Copy Link Print Information

Talazoparib tosylate

(Synonyms: BMN 673ts)
106 Cited Publications
Revisión del cliente

Based on 106 publication(s) in Google Scholar

Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.88%
  • No. CAS: 1373431-65-2
  • Fòrmula: C26H22F2N6O4S
  • Peso molecular:552.55
  • Almacenamiento:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Talazoparib tosylate Chemical Structure
    Talazoparib tosylate Chemical Structure
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
  • Experimental Validation Results for Talazoparib tosylate
No. CAS: 1373431-65-2
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Talazoparib tosylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Talazoparib tosylate

More
Customer Validation & Images
2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayCell Imaging/StainingIn Vivo Efficacy StudyWB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Imaging/Staining
  • 2D/3D Cell Culture and Differentiation
  • Cell Imaging/Staining
  • In Vivo Efficacy Study
  • WB

Ver todos los productos específicos de isoformas PARP

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Talazoparib tosylate Chemical Structure
    Talazoparib tosylate Chemical Structure
    1/16
  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Aug 5;12(8):1904-1921. [Abstract]

    Customer Validation
     Talazoparib (0.33 mg/kg, p.o., 70 days) diminished ascites accumulation and extended survival by ~30% in mice bearing ATX-sufficient OvCa.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

    Customer Validation
     Representative images of clonogenic assay results in PARP inhibitor (PARPi)-resistant OVCA433 cell in the presence of the indicated inhibitor for 12 d. ALKi, ALK inhibitor; LOR, Lorlatinib (250-500 nM); TALA, Talazoparib (100-200 nM); Comb, combination of Lorlatinib and Talazoparib.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Oct;3(10):1211-1227. [Abstract]

    Customer Validation
     Representative images of RAD51 with EdU/DAPI staining in OVCA433 cell treated with 0.25 μM PARP inhibitor (PARPi; Talazoparib) or 0.5 μM ALK inhibitor (ALKi; Lorlatinib), either alone or in combination, for 48 h.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

    Customer Validation
     Talazoparib (0.1–1250 nM, 5 days) suppressed the viability of CXorf67-WT and -KO Daoy C67 cells.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

    Customer Validation
     Talazoparib (5 nM, 0.5 or 24 h) combined with IR (2 Gy) resulted in further increases in γ-H2AX foci.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Dec 14;38(6):844-856.e7. [Abstract]

    Customer Validation
     Talazoparib (0.33 mg/kg, p.o., once a day for 5 days per week for 84 days) inhibited tumor growth in C67-KO and C67-re-expressing Daoy cells xenograft tumor models.

  • 1/16

    Talazoparib tosylate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2020 Sep:59:102923. [Abstract]

    Customer Validation
     Western Blot analyses of TP53, p21 and RAD51 in PARP inhibitor sensitive (SKCO1 and LS513) and resistant cell lines (SW1222 and SNU61) after treatment with Talazoparib for 48 h. Talazoparib decreases RAD51 protein expression in the two TP53 wild-type cell lines SKCO1 and LS513.

  • Talazoparib tosylate